Immune checkpoint inhibitors and their role in MM: pembrolizumab and durvalumab
What is the rationale for novel combination therapies?
Niels van de Donk
The biosimilar regulatory pathway
New antibody-drug conjugates for lymphoma
Follow-up CAR T-cell data so far